Investigating how immune responses to insulin peptides relate to type 1 diabetes activity
Responses to Hybrid Insulin Peptides as Biomarkers of Disease Activity in Human Type 1 Diabetes
['FUNDING_R01'] · UNIVERSITY OF COLORADO DENVER · NIH-10852827
This study is looking at how certain immune responses to special insulin-related proteins can help us understand how type 1 diabetes is changing in people, especially those who have just been diagnosed, so we can improve how we track and manage the condition.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF COLORADO DENVER (nih funded) |
| Locations | 1 site (Aurora, UNITED STATES) |
| Trial ID | NIH-10852827 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding how specific immune responses to Hybrid Insulin Peptides (HIPs) can indicate disease activity in individuals with type 1 diabetes (T1D). By analyzing blood samples from both T1D patients and healthy controls, the study aims to identify the presence and behavior of T cells that react to these unique insulin-related peptides. The research will explore how these immune responses change over time, particularly in patients who have recently been diagnosed with T1D. This could lead to better monitoring and understanding of the disease's progression.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with type 1 diabetes, particularly those who have recently experienced the onset of the disease.
Not a fit: Patients with type 2 diabetes or other forms of diabetes unrelated to autoimmune responses may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide new biomarkers for tracking disease activity in type 1 diabetes, potentially leading to improved management and treatment strategies.
How similar studies have performed: Previous research has shown promise in using immune responses as biomarkers in autoimmune diseases, suggesting that this approach could yield valuable insights in type 1 diabetes as well.
Where this research is happening
Aurora, UNITED STATES
- UNIVERSITY OF COLORADO DENVER — Aurora, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BAKER, ROCKY LEE — UNIVERSITY OF COLORADO DENVER
- Study coordinator: BAKER, ROCKY LEE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: autoimmune disorder, autoimmunity disease, Autoimmune Diseases